 |
 Video: What is a Stock Split?
|
|
|
| Adagio Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious disease. Co. is developing its primary product candidate, adintrevimab, for the prevention and treatment of coronavirus disease 2019 (COVID-19), the disease caused by the virus SARS-CoV-2 and its variants. Adintrevimab is designed to be a neutralizing antibody for both the prevention and treatment of COVID-19. Co. is also evaluating additional neutralizing antibodies targeting the receptor binding domain, as well as other subdomains within the spike protein for COVID-19. According to our ADGI stock split history records, ADGI has had 0 splits. | |
|
ADGI (ADGI) has 0 splits in our ADGI stock split history database.
Looking at the ADGI stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into ADGI shares, starting with a $10,000 purchase of ADGI, presented on a split-history-adjusted basis factoring in the complete ADGI stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
08/09/2021 |
|
| End date: |
09/12/2022 |
|
| Start price/share: |
$23.06 |
|
| End price/share: |
$4.64 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-79.88% |
|
| Average Annual Total Return: |
-76.93% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$2,012.40 |
|
| Years: |
1.09 |
|
|
|
|
|
